Douglas Fambrough, Dicerna CEO (Dicerna via YouTube)
November 18, 2021 07:15 AM ESTUpdated November 19, 04:17 PM
Deals

No­vo Nordisk swal­lows Dicer­na and its RNAi pipeline in $3.3B buy­out

John Carroll

Editor & Founder

Ear­ly this year re­searchers at No­vo Nordisk were beam­ing as they an­nounced the first drug iden­ti­fied in their RNAi al­liance with Dicer­na was head­ed in­to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times